A. Gouyette

发表

Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.

M. Mathieu, J. Morizet, N. Albin, 1993, Cancer research.

Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.

P. Beaune, I. de Waziers, F. Janot, 1992, Cancer research.

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.

S. Culine, M. Marty, I. Madelaine, 1994, Cancer research.

A new anticancer agent (LY186641) interferes with creatinine assay

J. Armand, G. Recondo, A. Gouyette, 1989, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics: statistical moment calculations.

A. Gouyette, 1983, Arzneimittel-Forschung.

Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model

M. Ducreux, P. Rougier, O. Rixe, 2004, Anti-cancer drugs.

Phenobarbital prevents the inhibitory effects of tumor necrosis factor on glutathione-S-transferase mu in primary culture rat hepatocytes.

S. Chouaib, L. Massaad-Massade, A. Gouyette, 1998, Anticancer Research.

Electrospray mass spectrometry for the characterization of the purity of natural and modified oligodeoxynucleotides.

J. Rossier, J. L. Le Caer, A. Deroussent, 1995, Rapid communications in mass spectrometry : RCM.

Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy.

F. Janot, V. Ribrag, J. Morizet, 1995, Leukemia & lymphoma.

Active metabolism of arachidonic acid by Kaposi sarcoma cells cultured from lung biopsies (KS-3); identification by HPLC and MS/MS of the predominant metabolite secreted as the 11,12-epoxy-eicosatrienoic acid.

L. Wahl, M. Gabellec, F. Dray, 1992, Biochimica et biophysica acta.

Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.

M. Foka, A. Gouyette, J. Richard, 1986, European journal of cancer & clinical oncology.

Tumour necrosis factor-α plasma levels after flavone acetic acid administration in man and mouse

J. Armand, S. Chouaib, D. Branellec, 1993 .

Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues

F. Janot, L. Massaad, C. Toussaint, 1994, Head & neck.

Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo.

F. Janot, V. Ribrag, L. Massaad, 1994, Leukemia research.

Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38

S. Koscielny, M. Bissery, J. Morizet, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and bioavailability of intramuscular preparations of ticarcillin.

M. Kitzis, A. Gouyette, J. Acar, 1982, The Journal of antimicrobial chemotherapy.

Metabolism of cytotoxic hydroxysterols in cultured cells. Chemical characterization of metabolites.

A. van Dorsselaer, A. Gouyette, B. Luu, 1988, Journal of steroid biochemistry.

Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter

T. Rikiyama, K. Cowan, M. Kim, 2000, Cancer Gene Therapy.

Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene.

M. Brenner, F. Besnard, O. Rixe, 1998, Cancer research.

Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits

G. Vassal, P. Rougier, R. Dzodic, 1996, Cancer Chemotherapy and Pharmacology.

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

G. Vassal, S. Koscielny, D. Valteau‐Couanet, 1995, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of high-dose melphalan in children and adults

O. Hartmann, J. Pico, A. Gouyette, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.

P. Hérait, P. Rougier, M. Riggi, 1993, Cancer research.

Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.

A. Le Cesne, T. le Chevalier, M. Marty, 1995, Lung cancer.

Verapamil‐reversing concentrations induce blood flow changes that could counteract in vivo the MDR‐1‐modulating effects

P. Rougier, A. Gouyette, J. Munck, 1994, Cancer.

Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy.

T. Fojo, V. Calvez, L. Mickley, 2000, Journal of the National Cancer Institute.

Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).

J. Droz, A. Gouyette, J. Rouessé, 1982, European journal of cancer & clinical oncology.

Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies.

J. Droz, N. Le bail, J. Pico, 1987, European journal of cancer & clinical oncology.

A revised structure of the antitumor drug elliptinium--amino(acid) adducts.

C. Paoletti, C. Auclair, A. Gouyette, 1985, Biochemical and biophysical research communications.

Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.

G. Vassal, L. Brugières, D. Valteau‐Couanet, 1990, Cancer research.

Cytoplasmic accumulation of ditercalinium in rat hepatocytes and induction of mitochondrial damage.

B. Roques, R. Fellous, E. Delain, 1988, Cancer research.

Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro

M. Bissery, A. Gouyette, G. Chabot, 2004, Cancer Chemotherapy and Pharmacology.

Reactivity of flavone acetic acid and its acyl glucuronide.

A. Gouyette, G. Chabot, 1991, Biochemical pharmacology.

Potent therapeutic activity of irinotecan (CPT‐11) and its schedule dependency in medulloblastoma xenografts in nude mice

C. Sainte-Rose, G. Vassal, M. Bissery, 1997, International journal of cancer.

Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse.

J. Armand, S. Chouaib, D. Branellec, 1993, European Journal of Cancer.

Stimulation of tumor growthin vitro andin vivo by suramin on the VX2 model

S. Koscielny, M. Juliéron, A. Gouyette, 1995, Investigational New Drugs.

Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.

C. Monneret, A. Gouyette, G. Atassi, 1989, Journal of medicinal chemistry.

Clastogenic inosine nucleotide as components of the chromosome breakage factor in scleroderma patients.

I. Emerit, A. Levy, C. Auclair, 1990, Archives of biochemistry and biophysics.

Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.

J. Armand, A. Gouyette, G. Chabot, 1992, Journal of chromatography.

High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors

J. Droz, P. Dietrich, J. Pico, 1991 .

Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

G. Vassal, S. Koscielny, D. Valteau‐Couanet, 1992, Blood.

Chronopharmacology of High-Dose Busulfan in Children 1

G. Vassal, F. Lévi, S. Koscielny, 2006 .

Chronopharmacology of high-dose busulfan in children.

G. Vassal, F. Lévi, S. Koscielny, 1993, Cancer research.

Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.

G. Vassal, E. Lucchi, C. Cappelli, 1998, Biochimie.

Metabolism of Irinotecan ( CPT-11 ) by CYP 3 A 4 and CYP 3 A 5 in Humans 1

E. Raymond, G. Vassal, V. Boige, 2000 .

Synthesis and antitumour activity of a new series of nitrosoureido sugars.

C. Monneret, A. Gouyette, P. Ardouin, 2000, European journal of medicinal chemistry.

Pharmacokinetics and Tolerability of Intravenous Trecovirsen (GEM®91), an Antisense Phosphorothioate Oligonucleotide, in HIV‐Positive Subjects

R. Tubiana, C. Katlama, P. Schechter, 1999, Journal of clinical pharmacology.

Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization

J. Armand, G. Recondo, M. Forni, 2004, Cancer Chemotherapy and Pharmacology.

Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars.

C. Monneret, A. Gouyette, G. Atassi, 1989, Journal of medicinal chemistry.

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations

G. Vassal, J. Morizet, M. Terrier-Lacombe, 1999, British Journal of Cancer.

Synthesis, spectroscopy, and cytotoxicity of glycosylated acetogenin derivatives as promising molecules for cancer therapy.

L. Sérani, R. Hocquemiller, O. Laprévote, 2000, Journal of medicinal chemistry.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

P. Hérait, J. Armand, A. Gouyette, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of high-dose busulfan in children

G. Vassal, O. Hartmann, J. Pico, 2004, Cancer Chemotherapy and Pharmacology.

Biosynthesis of Lewis antigenic glycolipid by cell-free extracts of human intestinal tumor cells cultured in serum-free medium.

P. Burtin, A. Gouyette, V. Liepkans, 1985, Biochemical and biophysical research communications.

Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress.

I. Emerit, J. Freitas, C. Auclair, 1997, Dermatology.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

A. Gouyette, G. Chabot, J. Guastalla, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic and Pharmacodynamic Advantages of Pirarubicin over Adriamycin after Intraarterial Hepatic Administration in the Rabbit VX 2 T \ imor Model 1

P. Hérait, P. Rougier, M. Riggi, 2006 .

Inefficiency of early prophylactic hemodialysis in cis-platinum overdose

G. Tchernia, F. Brivet, J. Dormont, 1986, Cancer Chemotherapy and Pharmacology.

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

A Gouyette, E. Raymond, G. Vassal, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patients.

L. Gutmann, P. Jaillon, M. Kitzis, 1989, The Journal of antimicrobial chemotherapy.

Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.

A. Faussat, V. Ribrag, L. Massaad-Massade, 1997, Anticancer research.

Is 600 mg / m 2 the Appropriate Dosage of Busulfan in Children Undergoing Bone Marrow Transplantation ?

G. Vassal, S. Koscielny, D. Valteau‐Couanet, 2003 .

Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard.

G. Vassal, A. Gouyette, M. Ré, 1988, Journal of chromatography.

Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis.

J. Droz, N. Man, J. Macquet, 1981, Cancer treatment reports.

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

G. Vassal, M. Bissery, J. Morizet, 1996, British Journal of Cancer.

Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases.

P. Rougier, M. Poupon, A. Gouyette, 1993, British Journal of Cancer.

Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer.

C. Théodore, J. Droz, J. Pico, 1991, European journal of cancer.

DNA-topoisomerase I, a new target for the treatment of neuroblastoma.

G. Vassal, C. Cappelli, J. Morizet, 1997, European journal of cancer.

Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.

G. Vassal, A. Watson, J. Morizet, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide (PEC protocol)].

J. Droz, J. Pico, A. Gouyette, 1990, Bulletin du cancer.

Experimental screening of 3 forms and 19 derivatives or analogs of ellipticine: oncostatic effect on l 1210 leukaemia and immunosuppressive effect of 4 of them.

T. A. Connors, G. Mathé, P. Potier, 1974, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma.

P. Beaune, I. de Waziers, F. Janot, 1993, Carcinogenesis.

Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.

J. Morizet, N. Albin, L. Massaad, 1993, Cancer research.

Flavone acetic acid: a nonlinear pharmacokinetic model

D. Kerr, S. Kaye, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer.

J. Bonneterre, P. Rougier, J. Bérille, 1993, European journal of cancer.

[Value and applications of pharmacogenetics in oncology and hematology].

N. Albin, A. Gouyette, L. Massade, 1997, Bulletin du cancer.

Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.

J. Armand, P. Carde, G. Recondo, 1993, European journal of cancer.

Characterization of the anti-tumour activity against solid tumours of a new nitrosoureido sugar: Cy 233

P. Dumont, A. Gouyette, G. Atassi, 2004, Cancer Chemotherapy and Pharmacology.

Drug resistance mechanisms in chronic lymphocytic leukemia.

A. Faussat, V. Ribrag, F. Dreyfus, 1996, Leukemia.

Stability of tetrahydrocannabinols II.

E. R. Garrett, A. Gouyette, H. Roseboom, 1978, Journal of pharmaceutical sciences.

undergoing bone marrow transplantation? Is 600 mg/m2 the appropriate dosage of busulfan in children

G. Vassal, S. Koscielny, D. Valteau‐Couanet, 2011 .

Chemical stability of ecomustine, a new antitumor agent in aqueous and biological media as assessed by high-performance liquid chromatography

A. Gouyette, G. Atassi, C. Gosse, 2004, Cancer Chemotherapy and Pharmacology.

Tumor cell biotransformation products of prostaglandin A1 with growth inhibitory activity.

F. Dray, A. Gouyette, B. Vulliez-le Normand, 1986, Biochemical and biophysical research communications.

Test dose-guided administration of cisplatin in an anephric patient: a case report.

J. Droz, V. Ribrag, J. Morizet, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumorigenicity of cerebellar primitive neuro‐ectodermal tumors in athymic mice correlates with poor prognosis in children

C. Sainte-Rose, G. Vassal, G. Riou, 1996, International journal of cancer.

Stability and preliminary pharmacokinetic studies of 1-(2-chloroethyl)-3-[1-(5'-paranitrobenzoyl-2',3'-isopropylidene)-alpha, beta-D-ribofuranosyl]-1-nitrosourea (RFCNU), a nonimmunosuppressive nitrosourea.

A. Gouyette, R. Lemoine, 1979, Cancer treatment reports.

Synthesis of deuterium-labelled elliptinium and its use in metabolic studies.

A Gouyette, A. Gouyette, 1988, Biomedical & environmental mass spectrometry.

Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals.

C. Paoletti, J. Le Pecq, A. Gouyette, 1980, Cancer treatment reports.

Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.

P. Hérait, P. Rougier, D. Elias, 1994, European journal of cancer.

GLC and HPLC Analyses of Cannabinoids in Biological Fluids and Applications

E. R. Garrett, C. A. Hunt, A. Gouyette, 1979 .

Effect on L1210 Leukemia, on Antibody Forming Cells, and on Macrophage Cytotoxicity of Ellipticine and 3 Derivatives

T. A. Connors, G. Mathé, P. Potier, 1976 .